

**A STUDY ON PATENT PROTECTION AND ACCESS TO AFFORDABLE
DRUGS**

By

Adelia Binti Adnan (2009432582)
Amira Haziqah Binti Zulkifli (2009457748)
Farah Saira Binti Abd Razak (2009449566)
Zuliana Binti Zulkifli (2009444118)

Submitted in Partial Fulfillment of the Requirements for the Bachelor Legal Studies
(Hons)

Universiti Teknologi MARA

Faculty of Law

December 2011

The students/ authors confirm that the work submitted is their own and that appropriate credit has been given where reference has been made to the works of others.

ABSTRACT

This project paper discusses on patent protection and access to affordable drugs. Chapter one of the project paper presents a background about the laws and issues involved in patent protection and access to affordable drugs. Chapter two of the project paper discusses on the relevant TRIPS provision, the flexibilities of the TRIPS Agreement and the Doha Paragraph 6 System. The flexibilities of the TRIPS Agreement include compulsory license, government use, parallel importation and permitted limited exceptions. Chapter three of the project paper discusses on the implementation of the TRIPS Agreement in various countries, which includes the United States, India, Brazil, South Africa and Malaysia. Chapter four explains the further barriers of the implementation of the TRIPS Agreement. The final chapter discusses the possible alternatives in enhancing access to affordable drugs.

ACKNOWLEDGEMENT

This research project has been carried out by a team consisting of Adelia binti Adnan, Amira Haziqah binti Zulkifli, Farah Saira binti Abd Razak and Zuliana binti Zulkifli. Writing this project paper requires support from many people and institution. First and foremost, we would like to thank our lecturers for Legal Research and Methodology (LAW 557), Prof. Madya Norha bt. Abu Hanifah and Puan Su'aida Dato' Safei, for the basic guidelines in preparing the project paper and the approval of the proposal. It is a pleasure to express gratitude for the assistance and guidance by our supervisor Prof. Dr. Lim Heng Gee who has been supportive and gives academic assistance for the achievement of the research objectives. Above and beyond the appreciation above, we are very grateful to our family members and friends for the moral supports given from the beginning until the completion of this research and for their prayers.

TABLE OF CONTENTS

Acknowledgement	ii
Abstract	iii
Table of Content	iv

CHAPTER ONE: A STUDY ON PATENT PROTECTION AND ACCESS TO AFFORDABLE DRUGS

1.0: Background of Study	1
1.1: Problem Statement	3
1.2: Objectives of Study	4
1.3: Literature Review	5
1.4: Research Methodology	8
1.5: Scope and Limitation	8
1.6: Significance of the Study	9

CHAPTER TWO: THE RELEVANT TRIPS PROVISION AND THE DOHA PARAGRAPH 6 SYSTEM

2.0: Introduction	10
2.1: TRIPS Agreement and Its Flexibilities	12
2.1.1: Compulsory Licence and Government Use	12
2.1.1.1: Compulsory Licence	12
2.1.1.2: Government Use	14
2.1.1.3: Ordinary Compulsory Licence and Government Use Order- Exception to Article 31 (b) and (f) as Allowed by Article 31 (k)	14
2.1.1.3.1: Prior Authorisation	14
2.1.1.3.2: Compulsory Licence Based on Anti-Competitive Practices- Article 31 (k) of TRIPS Agreement	17
2.1.2: Parallel Importation	19
2.1.3: Limited Exception	22
2.2: The Paragraph 6 Decision in 2003 and the Protocol Amending the TRIPS Agreement	24

2.2.1: The Paragraph 6 Decision in 2003	24
2.2.2: Protocol Amending the TRIPS Agreement	29
2.3: Conclusion	30

CHAPTER THREE: ADOPTION AND IMPLEMENTATION OF THE TRIPS AGREEMENT AND THE PROTOCOL AMENDING TRIPS AGREEMENT IN VARIOUS COUNTRIES

3.0: Introduction	32
3.1: United States Patent Legislations and Implementations	33
3.1.1: The Drug Price Competition and Patent Term Restoration Act 1984 (Hatch-Waxman)	33
3.1.2: The Schumer-McCain Legislation of 2002 (Section 812)	36
3.1.3: The Gregg-Schumer Amendment of 2003 (Section 1225)	37
3.1.4: Effects of Access to Generic Drugs in the United States	38
3.1.5: The United States Compliance with the TRIPS Agreement	39
3.2: The Indian Patent Legislations and Its Implementations	39
3.3: Brazilian Patent Legislations and Its Implementations	45
3.4: Malaysian Patent Legislations and Its Implementations	49
3.4.1: Compulsory Licence in Malaysia	49
3.4.2: Scope of the Compulsory Licence	50
3.4.3: Government Use	52
3.5: South African Patent Legislations and Its Implementations	52
3.5.1: Section 15C of the South African Medicines and Related Substances Control Act (MRSCA) 1965 and Its Compliance with the TRIPS Agreement	53
3.6: Conclusion	57

CHAPTER FOUR: FURTHER CHALLENGES AND BARRIERS TO AFFORDABLE DRUGS

4.0: Introduction	59
4.1: Counterfeit Medicines	59
4.2: Trade Agreements	61